Which radiographic feature is associated with moderate to severe disease of anterior teeth?

Get ready for the FPC 2 Exam 1. Master the essentials with our interactive quizzes featuring detailed explanations and hints. Ace your exam with confidence!

Multiple Choice

Which radiographic feature is associated with moderate to severe disease of anterior teeth?

Explanation:
The sign that best shows moderate to severe periodontal disease on a radiograph is a noticeable reduction in the height of the alveolar bone around the tooth roots. When disease progresses, the supporting bone recedes, so the remaining alveolar bone height becomes prominently diminished, which radiographs capture clearly. This direct loss of bone height reflects the extent of bone destruction and correlates with more advanced disease in the anterior region. Other options are less indicative of overall severity. A blunted crest can indicate vertical defects but isn’t as reliable for gauging how widespread the disease is. A crown-to-root ratio >1:2 describes a consequence of bone loss and tooth prognosis rather than the current radiographic severity. Normal crest height would imply little to no bone loss, not moderate to severe disease.

The sign that best shows moderate to severe periodontal disease on a radiograph is a noticeable reduction in the height of the alveolar bone around the tooth roots. When disease progresses, the supporting bone recedes, so the remaining alveolar bone height becomes prominently diminished, which radiographs capture clearly. This direct loss of bone height reflects the extent of bone destruction and correlates with more advanced disease in the anterior region.

Other options are less indicative of overall severity. A blunted crest can indicate vertical defects but isn’t as reliable for gauging how widespread the disease is. A crown-to-root ratio >1:2 describes a consequence of bone loss and tooth prognosis rather than the current radiographic severity. Normal crest height would imply little to no bone loss, not moderate to severe disease.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy